Context Therapeutics Net Tangible Assets Over Time
| CNTX Stock | USD 1.52 0.02 1.33% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Context Therapeutics Performance and Context Therapeutics Correlation. Context |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Context Therapeutics. If investors know Context will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Context Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.88) | Return On Assets (0.19) | Return On Equity (0.30) |
The market value of Context Therapeutics is measured differently than its book value, which is the value of Context that is recorded on the company's balance sheet. Investors also form their own opinion of Context Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Context Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Context Therapeutics' market value can be influenced by many factors that don't directly affect Context Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Context Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Context Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Context Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Tangible Assets Analysis
Compare Context Therapeutics and related stocks such as Terns Pharmaceuticals, Amylyx Pharmaceuticals, and Acumen Pharmaceuticals Net Tangible Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TERN | (22.7 M) | (22.7 M) | (22.7 M) | (22.7 M) | (22.7 M) | (22.7 M) | (22.7 M) | (22.7 M) | (22.7 M) | (90.8 M) | (117.4 M) | 172.2 M | 276.9 M | 318.5 M | 334.4 M |
| ABOS | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (18.6 M) | 225.2 M | 188.8 M | 217.1 M | 227.9 M |
| INZY | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (33.2 M) | 158.1 M | 109.3 M | 118.4 M | 136.2 M | 74.5 M |
| XFOR | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (44.5 M) | (77.1 M) | 102.1 M | 45.7 M | 47.1 M | 56.7 M | 65.2 M | 68.5 M |
| SPRO | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (37.5 M) | 84.6 M | 115.5 M | 74.6 M | 132 M | 88.3 M | 75.9 M | 87.3 M | 70.9 M |
| BOLT | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (45.8 M) | (104.9 M) | 250.1 M | 171.5 M | 197.2 M | 207.1 M |
| CHRS | 63.2 M | 63.2 M | 63.2 M | 63.2 M | 63.2 M | (9.8 M) | 17 M | 28.3 M | (42.2 M) | 101.7 M | 277.4 M | 97.7 M | (143.3 M) | (164.9 M) | (156.6 M) |
| DAWN | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (54.2 M) | 281.1 M | 332 M | 381.8 M | 400.9 M |
| NXTC | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (46.9 M) | 321.5 M | 293.7 M | 233.4 M | 167.5 M | 192.7 M | 173.2 M |
| CTMX | (81.2 M) | (81.2 M) | (81.2 M) | (81.2 M) | (81.2 M) | 123.4 M | 75.8 M | 67.3 M | 128.5 M | 48.9 M | 47.7 M | 87.4 M | (2.4 M) | (2.8 M) | (2.7 M) |
| ASMB | 34.5 M | 34.5 M | 17.8 M | 24.5 M | 16.8 M | 77.1 M | 38.2 M | 113.1 M | 169 M | 231.6 M | 198.9 M | 168.9 M | 82.7 M | 95.1 M | 107.5 M |
| ZURA | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (32.1 M) | (28.9 M) | (30.3 M) |
| ANNX | (46.2 M) | (46.2 M) | (46.2 M) | (46.2 M) | (46.2 M) | (46.2 M) | (46.2 M) | (46.2 M) | (64.2 M) | (100.5 M) | 344.3 M | 231.9 M | 231.2 M | 265.9 M | 279.2 M |
| INAB | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (9.2 M) | (16.6 M) | 38.2 M | 38.2 M | 43.9 M | 46.1 M |
| WVE | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | 153.5 M | 134.9 M | 139.6 M | 73.3 M | 63.7 M | 90.7 M | 40.4 M | (37.2 M) | (33.5 M) | (31.8 M) |
Context Therapeutics and related stocks such as Terns Pharmaceuticals, Amylyx Pharmaceuticals, and Acumen Pharmaceuticals Net Tangible Assets description
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.My Equities
My Current Equities and Potential Positions
| Context Therapeutics | CNTX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Pennsylvania; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.52
Additional Tools for Context Stock Analysis
When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.